Multiple cycles of recombinant human thrombopoietin therapy in a patient with chronic refractory idiopathic thrombocytopenic purpura

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 4, 2005, Pages 291-295

  Hua, Baolai ^a   Zou, Nong ^a   Wang, Shujie ^a   Zhu, Tienan ^a   Zhao, Yongqiang ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Idiopathic thrombocytopenic purpura; Thrombopoietin; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT THROMBOPOIETIN; VINCRISTINE;

ADULT; ARTICLE; CASE REPORT; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; MUCOSAL BLEEDING; PETECHIA; PRIORITY JOURNAL; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE COUNT;

EID: 18944407713     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000169223.46420.86     Document Type: Article

References (24)

1. Kaushansky K. Thrombopoietin. N Engl J Med 1998; 339:746-754.
2. von dem Borne A, Folman C, van den Oudenrijn S, Linthorst G, de Jong S, de Haas M. The potential role of thrombopoietin in idiopathic thrombocytopenic purpura. Blood Rev 2002; 16:57-59.
3. Kosugi S, Kurata Y, Tomiyama Y, Tahara T, Kato T, Tadokoro S, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Heamatol 1996; 93:704-706.
4. Usuki K, Tahara T, Iki S, Endo M, Osawa M, Kitazume K, et al. Serum thrombopetin level in various hematological disease. Stem Cell 1996; 14:558-565.
5. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, Patel S, Reddy SP, Hoots WK, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997; 126:673-681.
6. Basser RL, Rasko JE, Claeke K, Cebon J, Green MD, Hussein S, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348:1279-1281.
7. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002; 100:728-730.
8. Rice L, Nichol JL, McMillan R, Roskos LK, Bacile M. Cyclic immune thrombo-cytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol 2001; 68:210-214.
9. Song HF, Liu XW, Tang ZM. Pharmacokinetics and peripheral platelet counts after a single dose of recombinant human thrombopoietin in rhesus monkeys [in English]. Acta Pharmacol Sin 1999; 20:244-248.
10. Liu XW, Yang K, Lu Q-J, Tang ZM. Pharmacokinetics, and peripheral platelet counts and anti-thrombopoietin antibodies after multi-dosing of recombinant human thrombopoietin in macaca mulatto. Chin J Phamarcol Toxicol 2000; 14:227-231.
11. Jiang JL, Zhao YQ, Shan YD, Wu YJ. Pharmacokinetics after a single subcutaneous injection of recombinant human thrombopoietin in human. Chin J Clin Pharmacol 2001; 17:284-286.
12. Zhao YQ, Jiang JL, Jiao L, Pan JQ, Chen SC, Wang SJ, et al. Clinical tolerance of recombinant human thrombopoietin. Chin J Med 2001; 81:1508-1511.
13. Bai CM, Xu GX, Zhao YQ, Han SM, Shan YD. A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor. Acta Acad Med Sin 2004;26:437-441.
14. Zhao YQ, Wang QY, Zhai M, Xu J, Chen XQ, Liu WL, et al. A multi-center clinical trial of recombinant human thrombopoietin in chronic refractory idiopathic thrombocytopenic purpura. Chin J Intern Med 2004; 43:608-610.
15. Abina MA, Tulliez M, Duffour MT, Debili N, Lacout C, Villeval JL, et al. Thrombopoietin (TPO) knockout phenotype induced by cross-reactive antibodies against TPO following injection of mice with recombinant adenovirus encoding human TPO. J Immunol 1998; 160:4481-4489.
16. Dale DC, Nichol JL, Rich DA, Best DM, Slichter SL, Sheridan W, et al. Chronic thrombocytopenia is induced in dogs by development of cross-reacting antibodies to the MpL ligand. Blood 1997; 90:3456-3461.
17. Bain BJ. Bone marrow aspirate of healthy subjects. Br J Haematol 1996; 94:206-209.
18. Cines DB, Bianchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346:955-1008.
19. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JM, Slichter SJ, et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80:33-40.
20. George JN, Kojouri K, Perdue JJ, Vesely SK. Management of patients with chronic, refractory idiopathic thrombocytopenic purpura. Semin Hematol 2000; 37:290-298.
21. Horie K, Miyazaki H, Hagiwara T, Tahara E, Matsumoto A, Kadoya J, et al. Action of thrombopoietin at the megakaryocyte progenitor level is critical for the subsequent proplatelet production. Exp Hematol 1997; 25:169-176.
22. Li J, Yang C, Xia YP, Bertino A, Glaspy J, Roberts M, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241-3248.
23. Basser RL, O'Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002; 99:2599-2602.
24. Ikeno K, Koike K, Takeshita A, Shinjo K, Higuchi T, Nakabayashi T, et al. Stressful delivery influences circulating thrombopoitin (TPO) levels in newborns: possible role for cortisol in TPO-mpl binding. Early Hum Dev 2000; 58:225-235.